1. Home
  2. CRVS

CRVS

Corvus Pharmaceuticals Inc.

Logo Corvus Pharmaceuticals Inc.

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

as 04-17-2024 10:32am EST

$
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical engaged in developing drugs and antibodies that target the critical cellular elements of the immune system. It focuses on the development of immune modulator product candidates to treat COVID-19, T-cell lymphomas, other cancers, and autoimmune diseases. The company's main product candidate is CPI-006 which is a potent humanized monoclonal antibody that is designed to react with a specific site on CD73. Its other product candidates are CPI-818, CPI-935, CPI-182 and Ciforadenant.

Founded: 2014 Country:
United States
United States
Employees: N/A City: BURLINGAME
Market Cap: 79.9M IPO Year: 2016
Target Price: $6.00 AVG Volume (30 days): 200.3K
Analyst Decision: Buy Number of Analysts: 5
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -0.56 EPS Growth: N/A
52 Week Low/High: $0.98 - $4.19 Next Earning Date: 05-06-2024
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): N/A

Share on Social Networks: